Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
Ocular Therapeutix (NASDAQ: OCUL) will participate in multiple scientific conferences in October 2025 to present clinical and company data on retina therapies.
Key appearances: American Academy of Optometry (Boston, Oct 8–11) — poster on one‑year HELIOS Phase 1 OTX‑TKI safety and efficacy on Oct 9, 4:30–6:30 PM ET by Trung Tran; Eyecelerator @ AAO (Orlando, Oct 16) — company showcase by Peter K. Kaiser, MD on Oct 16, 1:15–2:45 PM ET; American Academy of Ophthalmology (Orlando, Oct 18–20) — on‑demand poster on macular fluid and vascular leakage after a single axitinib intravitreal hydrogel, presented by Margaret Chang, MD, MS. Exact times may change.
Ocular Therapeutix (NASDAQ: OCUL) parteciperà a diverse conferenze scientifiche in ottobre 2025 per presentare dati clinici e aziendali sulle terapie retiniche.
Apparizioni chiave: American Academy of Optometry (Boston, 8–11 ottobre) — poster su sicurezza ed efficacia di HELIOS Phase 1 OTX‑TKI a un anno il 9 ottobre, dalle 16:30 alle 18:30 ET da Trung Tran; Eyecelerator @ AAO (Orlando, 16 ottobre) — presentazione aziendale da Peter K. Kaiser, MD il 16 ottobre, dalle 13:15 alle 14:45 ET; American Academy of Ophthalmology (Orlando, 18–20 ottobre) — poster on-demand su fluido maculare e perdita vascolare dopo un idrogel intravitreale di axitinib, presentato da Margaret Chang, MD, MS. Gli orari esatti possono variare.
Ocular Therapeutix (NASDAQ: OCUL) participará en varias conferencias científicas en octubre de 2025 para presentar datos clínicos y de la empresa sobre terapias de retina.
Apariciones clave: American Academy of Optometry (Boston, 8–11 de octubre) — póster sobre seguridad y eficacia a un año de HELIOS Phase 1 OTX‑TKI a cargo de Trung Tran; Eyecelerator @ AAO (Orlando, 16 de octubre) — presentación de la empresa por Peter K. Kaiser, MD el 16 de octubre, de 1:15 a 2:45 PM ET; American Academy of Ophthalmology (Orlando, 18–20 de octubre) — póster a demanda sobre líquido macular y fuga vascular tras un hidrogel intravítreo de axitinib, presentado por Margaret Chang, MD, MS. Los horarios exactos pueden cambiar.
Ocular Therapeutix (NASDAQ: OCUL)은 2025년 10월 Retina 치료에 관한 임상 및 회사 데이터를 발표하기 위해 여러 학술 컨퍼런스에 참가합니다.
주요 발표: American Academy of Optometry (보스턴, 10월 8–11일) — Trung Tran이 발표하는 10월 9일 ET 4:30–6:30 PM에 헬리오스 1상 OTX‑TKI 1년 안전성·효능 포스터; Eyecelerator @ AAO (올랜도, 10월 16일) — Peter K. Kaiser, MD의 회사 소개 10월 16일 1:15–2:45 PM ET; American Academy of Ophthalmology (올랜도, 10월 18–20일) — 단일 주입된 축시티닙 유리체 하이드로젤 후의 망막액 및 혈관 누출에 관한 주문형 포스터, Margaret Chang, MD, MS 발표. 정확한 시간은 변동될 수 있습니다.
Ocular Therapeutix (NASDAQ: OCUL) participera à plusieurs conférences scientifiques en octobre 2025 pour présenter des données cliniques et de l’entreprise sur les thérapies rétiniennes.
Présences clés : American Academy of Optometry (Boston, 8–11 octobre) — poster sur la sécurité et l’efficacité à un an du HELIOS Phase 1 OTX‑TKI par Trung Tran; Eyecelerator @ AAO (Orlando, 16 octobre) — présentation de l’entreprise par Peter K. Kaiser, MD le 16 octobre, 13h15–14h45 ET; American Academy of Ophthalmology (Orlando, 18–20 octobre) — poster à la demande sur le liquide maculaire et la fuite vasculaire après un hydrogel intravitréen d’axitinib, présenté par Margaret Chang, MD, MS. Les heures exactes peuvent changer.
Ocular Therapeutix (NASDAQ: OCUL) wird im Oktober 2025 an mehreren wissenschaftlichen Konferenzen teilnehmen, um klinische und unternehmensbezogene Daten zu Netzhaut-Therapien vorzustellen.
Wichtige Auftritte: American Academy of Optometry (Boston, 8.–11. Oktober) — Poster zu einjähriger Sicherheit und Wirksamkeit von HELIOS Phase 1 OTX‑TKI von Trung Tran; Eyecelerator @ AAO (Orlando, 16. Oktober) — Unternehmensvorstellung von Peter K. Kaiser, MD am 16. Oktober, 13:15–14:45 Uhr ET; American Academy of Ophthalmology (Orlando, 18.–20. Oktober) — On-demand Poster zu Makula-Flüssigkeit und Gefäßleckage nach einem AXITINIB-Intravitrealen Hydrogel, vorgestellt von Margaret Chang, MD, MS. Genaue Zeiten können sich ändern.
Ocular Therapeutix (NASDAQ: OCUL) ستشارك في عدة مؤتمرات علمية في أكتوبر 2025 لعرض بيانات سريرية وبيانات الشركة حول علاجات الشبكية.
التواجدات الرئيسية: American Academy of Optometry (بوسطن، 8–11 أكتوبر) — ملصق حول أمان وفعالية HELIOS Phase 1 OTX‑TKI لمدة عام من إعداد Trung Tran؛ Eyecelerator @ AAO (أورلاندو، 16 أكتوبر) — عرض الشركة من قبل Peter K. Kaiser, MD في 16 أكتوبر، 1:15–2:45 مساءً بتوقيت شرق الولايات المتحدة؛ American Academy of Ophthalmology (أورلاندو، 18–20 أكتوبر) — ملصق حسب الطلب عن سائل البقعة الدمعية وتسرّب الأوعية بعد هيدروجيل داخلي للأكسيتينيب، قدمته Margaret Chang, MD, MS. قد تتغير الأوقات الدقيقة.
Ocular Therapeutix (NASDAQ: OCUL) 将于2025年10月参加多场科学会议，展示视网膜治疗的临床和公司数据。
关键亮相：American Academy of Optometry（波士顿，10月8–11日）— 由Trung Tran 在 10月9日，东部夏令时16:30–18:30 举办的 HELIOS Phase 1 OTX‑TKI 一年安全性与有效性海报； Eyecelerator @ AAO（奥兰多，10月16日）— Peter K. Kaiser, MD 的公司展示，时间为 10月16日，1:15–2:45 PM ET； American Academy of Ophthalmology（奥兰多，10月18–20日）— 关于单次肌注的阿西替尼母液的黄斑水肿和血管渗漏的按需海报，由 Margaret Chang, MD, MS 主讲。具体时间可能会有变动。
- None.
- None.
BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in October 2025.
Upcoming Scientific Conferences (all times ET):
American Academy of Optometry: October 8 - 11, 2025
Boston, Massachusetts
- Poster Title: Safety and Efficacy of OTX-TKI in Moderately Severe to Severe NPDR: One Year Results from the HELIOS Phase 1 Trial
Session Date/Time: Thursday, October 9, 2025, 4:30 – 6:30 PM ET
Presenter: Trung Tran, OD, Senior Medical Director at Ocular Therapeutix
Eyecelerator @ AAO 2025: October 16, 2025
Orlando, Florida
- Company Presentation: Ocular Therapeutix: Redefining the Retina Experience
Session: Presenting Company Showcases
Session Date/Time: Thursday, October 16, 2025, 1:15 – 2:45 PM ET
Presenter: Peter K. Kaiser, MD, Chief Development Officer
American Academy of Ophthalmology: October 18 - 20, 2025
Orlando, Florida
- On-Demand Poster Title: Macular Fluid Volume and Retinal Vascular Leakage Analysis Following a Single Axitinib Intravitreal Hydrogel in Diabetic Retinopathy
Session Date/Time: On-demand posters available for viewing throughout duration of the congress.
Presenter: Margaret Chang, MD, MS
Exact medical conference presentation times may be subject to change.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), with a Phase 3 clinical program for non-proliferative diabetic retinopathy (NPDR) planned to be initiated imminently.
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Explore the Company’s new corporate branding and follow the Company on its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
When will Ocular Therapeutix (OCUL) present HELIOS Phase 1 one‑year results at AAO 2025?
What will OCUL present at Eyecelerator @ AAO on Oct 16, 2025?
Which OCUL research will be available on‑demand at the American Academy of Ophthalmology Oct 18–20, 2025?
How can investors access Ocular Therapeutix conference materials during October 2025?
Who are the OCUL presenters at the October 2025 conferences?
Are the listed presentation times for Ocular Therapeutix final for October 2025?
